P352 New therapy, new adherence idea?

Better quality of life (QoL) and health conditions, fewer exarcebations are reported by patients taking the new therapy with enhancers CFTR channel. Our study evaluates adherence who take modulator drugs correlation between higher lung function (FEV1), adherence. To 13 followed at CF support service Leghorn Hospital, Pediatric Unit, 6 male, 7 female mean age 28,8 y. from y to 34 y, treated for least three months modulator, administered MMAS CFQ-R evaluate Quality respectively. Fev1 data before starting time enrolment were collected medical records In our sample (53.85%) showed low adherence, (46,15%) medium The median value according MMSA scale it was even 5 values ranging 1 7. No high level or greater than Fev increased 17% (from 56% 73%) increase is significant, more marked in group (18,5%) that (15,8%) significant both groups (p = 0.0005 e p 0.0013 respectively) 69% have a good QoL (> 75) Improvements subjects (+ 22,5%) compared reduced (+10,5%) seem correlate improvement report an their conditions QoL, despite this not hight. This preliminary will be integrated other regarding emotional state personality structure.